Ipamorelin Dosage: What the Studies Actually Administered

Search "ipamorelin dosage" and you will be handed a number within seconds — usually 200 to 300 micrograms, injected under the skin, once or twice a day, on an empty stomach. This article's job is to tell you where that number actually comes from, and the honest answer is not a clinical trial, a label, or a prescriber guideline. It comes from bodybuilding websites.

Here is the finding that reframes the entire question, checked directly rather than assumed: not one published human study has ever administered ipamorelin subcutaneously. Every human exposure in the literature went in intravenously, in a hospital or a clinical pharmacology unit, by infusion. FDA said so itself when it evaluated the compound: "FDA did not identify PK or PD information for the proposed SC route of administration of ipamorelin (free base) or ipamorelin acetate... There is no PK/PD information for any other routes of administration⁴." Subcutaneous injection is the only way ipamorelin is actually sold and used. It is also the one route on which no human data exists at all.

Every ipamorelin dose ever given to a human, in one table

That is the complete list. Two studies, both intravenous, twenty-six years apart.

Study one: five ascending IV infusion rates, expressed in nanomoles

The only human pharmacokinetic study of ipamorelin describes its own dosing precisely, and in a unit most dosage pages never mention: "a dose escalation design comprising 5 different infusion rates (4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutes) with eight healthy male subjects at each dose level¹." Those are nanomoles per kilogram, delivered as a fifteen-minute intravenous infusion — a molar dose, weight-based, given by drip, which is about as far from "200 mcg in a subcutaneous syringe" as a dosing instruction can get.

Because ipamorelin's molecular weight is a fixed, published number (711.9 g/mol⁸), those molar figures can be converted to the mass units a vial is labeled in. That conversion is arithmetic on published numbers, not a recommendation, and it is worth running because it reveals what the study was actually designed around: 4.21 nmol/kg works out to roughly 3 µg/kg, and the four steps above it land almost exactly on 10, 30, 60, and 100 µg/kg. At a 70 kg body weight, that ladder spans about 210 micrograms at the bottom rung to about 7 milligrams at the top — a thirty-three-fold range, all of it infused rather than injected.

One detail about that study is worth reporting even though it complicates the picture. The published abstract says eight subjects per dose level. FDA, reading the same paper for its own evaluation, describes it differently: "Forty-eight subjects were enrolled. Five groups with 6 healthy male subjects per group received a range of ipamorelin doses... and 2 subjects per group received placebo⁴." On FDA's reading, thirty people actually received ipamorelin, not forty — the abstract's "eight per level" being the group size with its placebo subjects included. FDA also records something the abstract leaves out entirely: "The lowest dose of 4.21 nmol/kg group and placebo groups were not included in the PK/PD analysis due to negligible GH levels⁴." The smallest dose tested produced too little growth hormone to model. This article states both readings rather than choosing the one that makes the evidence base sound larger.

Study two: 0.03 mg/kg intravenously, twice daily — and it missed

The only trial that tested ipamorelin against a clinical outcome states its own regimen in one line: "intravenous infusions of 0.03-mg/kg ipamorelin vs placebo twice daily, on postoperative day 1 to 7 or hospital discharge²." That is 30 µg/kg per dose — about 2.1 mg for a 70 kg adult, twice a day — given to 114 patients recovering from bowel-resection surgery. The dose was well tolerated: 87.5% of the ipamorelin group reported any adverse event versus 94.8% on placebo². It did not work. Median time to a first tolerated meal was 25.3 hours on ipamorelin versus 32.6 hours on placebo, and the trial's own conclusion is unambiguous: "There were no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses²." Our standalone evidence review covers that result in full. What matters here is narrower: this is the only ipamorelin regimen in existence that was ever tested for whether it helped anyone, and the answer was no.

The animal doses are real — and they are not human doses

Ipamorelin's discovery paper contains genuine dose-response data, and it is worth naming exactly what kind. In pentobarbital-anesthetized rats, ipamorelin released growth hormone with an ED50 of 80 ± 42 nmol/kg; in conscious swine, an ED50 of 2.3 ± 0.03 nmol/kg³. The paper's headline selectivity finding is tied to a dose multiple: ipamorelin did not raise ACTH or cortisol "even at doses more than 200-fold higher than the ED50 for GH release³" — in pigs. Those are real, published, quantified numbers from a peer-reviewed paper, and every one of them describes a rat or a pig. None of them establishes a human dose, and this article does not scale them into one.

What FDA found people are actually selling — in FDA's own words

The most useful survey of circulating ipamorelin "doses" is not a vendor page; it is FDA's own briefing document, which inventoried the market as part of deciding whether to allow compounding. The product formally nominated for the federal compounding list is "a 2000 mcg/mL lyophilized powder for subcutaneous (SC) injection⁴" — a concentration, not a dose. What FDA then found on the open market spans three orders of magnitude in a single paragraph: one wellness clinic markets ipamorelin acetate in oral, nasal, intravenous, and subcutaneous formulations, the last "supplied as a dose of 150 mcg per day via single injections"; "yet another wellness clinic website markets ipamorelin as available in formulations of 15 mg injections, 300 mg and 500 mg oral troches, and 750 mg RDT⁴." A 150-microgram daily injection and a 15-milligram injection are a hundred-fold apart. Both were being sold as ipamorelin, at the same time, to the same public.

FDA's conclusion after weighing all of it: "we conclude based on available clinical information that the evidence of effectiveness for GHD or POI is limited for any ROA, and there are no data to support the effectiveness of ipamorelin (free base) or ipamorelin acetate for the proposed SC route of administration for these medical conditions⁴." A live re-check of FDA's current 503A Bulks List, updated May 14, 2026 and text-extracted in full for this article, confirms ipamorelin appears in none of its three nomination categories today⁶. A DailyMed search returns zero results against a database published August 6, 2026 — there is no FDA-approved ipamorelin product, and therefore no label with a dosage section to quote⁵.

Where "200 to 300 mcg" actually comes from

A 2026 peer-reviewed narrative review in Frontiers in Endocrinology — a review, not a trial — did something unusually useful: it built a table that puts clinical-study dosing and internet self-administration protocols side by side, in separate columns, so the two can't be mistaken for each other. Ipamorelin's clinical column contains exactly what this article reported above: "4.21–140.45 nmol/kg IV infusion, single administration." Its other column reads "200-300 µg SC 2 or 3 injections/day, timed to mimic natural GH pulses, often used in combination with CJC-1295 (without DAC); typical cycle: 8–12 weeks on, followed by 4–6 weeks off⁷." The two sources that row cites are a peptide-vendor protocol page and a supplement-company blog post, named in the review's own bibliography.

The review states in its own words what that table is and is not, and it deserves quoting in full rather than summarizing: "The online protocols included in this table are not evidence-based treatment strategies, MUST NOT be interpreted as clinically validated or safe, and are presented solely as anthropological/behavioral data describing self-administration practices and the informational environment encountered in real-world clinical care⁷." That is a peer-reviewed source documenting a forum number as a behavior worth studying — not endorsing it as a dose. Any page that lifts the 200-300 µg figure out of that table and drops the surrounding sentence has converted an observation about what people do into an instruction about what to take.

For its own part, the review places ipamorelin's route in the same table as "i.v./s.c." while its underlying citation for both is the intravenous study⁷ — a small illustration of how quickly the subcutaneous route acquires an evidentiary weight nothing actually gave it.

Comparing that number to the numbers that were tested

Set the circulating figure against the tested ones and the mismatch runs in a direction most pages never mention. A 200-300 µg injection is roughly the size of the study's lowest rung — the ~3 µg/kg dose that works out to about 210 µg at 70 kg, and the one FDA notes was dropped from the analysis for producing negligible growth hormone⁴. The trial dose that was actually tested against a clinical outcome, 0.03 mg/kg twice daily, is closer to 2.1 mg per injection at the same body weight — seven to ten times larger than the figure that circulates.

That comparison is worth stating carefully, because it does not mean the forum number is "too low." Route changes everything: a fifteen-minute intravenous infusion and a subcutaneous injection deliver drug to the bloodstream on entirely different curves, and nobody has published the study that would tell you how the two compare in a person. That study is precisely the one FDA looked for and could not find. The comparison establishes something narrower and more useful: the number circulating as "the ipamorelin dose" has no measured relationship to any dose a human study ever administered, in either direction.

Banned in tested sport, at any dose

This part carries no ambiguity. WADA's 2026 Prohibited List names ipamorelin explicitly under section S2.2.4, "growth hormone secretagogues (GHS) and their mimetics," within a class headed "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)" and flagged "All prohibited substances in this class are non-Specified Substances⁹." There is no dose threshold, no in-competition-only window, and no micro-dose that falls outside the class. If you are tested under any WADA-code sport, ipamorelin is a positive at any amount, by any route.

The bottom line

There is no established ipamorelin dose, and saying so is the accurate answer rather than an evasive one. No FDA-approved product exists, so no label specifies one. Two human studies exist, both intravenous: five ascending infusion rates in healthy men, and 0.03 mg/kg twice daily in surgical patients, which missed its endpoint. Not one published human study has used the subcutaneous route the market sells — FDA looked for that data specifically and reported finding none. The 200-300 µg figure that dominates search results is real in the sense that people genuinely use it, and it is documented in a peer-reviewed table for exactly that reason, with a printed warning that it must not be read as clinical validation. If you have an actual dose from a licensed prescriber, our ipamorelin reconstitution calculator will convert it into a syringe volume — arithmetic on the number you enter, never a suggestion of what that number should be. If you are weighing ipamorelin against the GH-axis compounds this site has reviewed sellers for, our ipamorelin-versus-sermorelin comparison, our three-way comparison with CJC-1295, and our review of the CJC-1295/ipamorelin pairing are the companion reads.